Department of Diagnostic Radiology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Jpn J Radiol. 2012 Nov;30(9):735-42. doi: 10.1007/s11604-012-0116-1. Epub 2012 Aug 28.
To retrospectively investigate the short-term therapeutic effects and adverse effects associated with the use of miriplatin-lipiodol suspension for transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC), using TACE with cisplatin-lipiodol suspension as the historical control.
The study was conducted on 48 and 50 consecutive patients with HCC who underwent TACE with miriplatin-lipiodol suspension and cisplatin-lipiodol suspension, respectively. Therapeutic effect was evaluated by mRECIST. Adverse effects were graded by CTCAE, version 4.0. The therapeutic and adverse effects were compared using Fisher's exact test and multivariate logistic regression.
Complete remission, partial response, stable disease and progressive disease were observed in 37.5, 18.8, 33.3 and 10.4 % of patients in the miriplatin group, with the corresponding percentages being 54.0, 32.0, 14.0 and 0.0 %, respectively, in the cisplatin group. The short-term therapeutic effects were statistically significantly worse in the miriplatin group than in the cisplatin group, even after adjustment for tumor size and Child-Pugh class. The rates of nausea and serum creatinine elevation were statistically significantly lower in the miriplatin group (p < 0.05).
TACE using miriplatin-lipiodol suspension yielded worse short-term responses than cisplatin-lipiodol suspension; however, the rates of adverse events were significantly lower in the miriplatin group.
回顾性分析米立铂碘油混悬液经导管动脉化疗栓塞术（TACE）治疗肝细胞癌（HCC）的短期疗效和不良反应，并与顺铂碘油混悬液 TACE 作为历史对照。
本研究纳入了分别接受米立铂碘油混悬液和顺铂碘油混悬液 TACE 的 48 例和 50 例 HCC 患者。采用 mRECIST 评估疗效，采用 CTCAE 4.0 分级评估不良反应。采用 Fisher 确切检验和多因素 logistic 回归比较两种治疗方法的疗效和不良反应。
米立铂组完全缓解、部分缓解、疾病稳定和疾病进展的比例分别为 37.5%、18.8%、33.3%和 10.4%，顺铂组分别为 54.0%、32.0%、14.0%和 0.0%。即使调整肿瘤大小和 Child-Pugh 分级后，米立铂组的短期疗效也明显差于顺铂组。米立铂组恶心和血清肌酐升高的发生率明显低于顺铂组（p < 0.05）。
与顺铂碘油混悬液 TACE 相比，米立铂碘油混悬液 TACE 的短期疗效较差，但米立铂组不良反应发生率明显较低。
